Drug Profile
CX 397
Latest Information Update: 16 Nov 2006
Price :
$50
*
At a glance
- Originator Nikko Kyodo
- Developer Japan Energy Corporation; Nikko Kyodo
- Class Antithrombotics
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary thrombosis; Disseminated intravascular coagulation; Thrombosis